BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has published an article in Neurobiology of Disease describing new preclinical data for the investigational anti-α-synuclein antibody ABBV-0805. The publication includes data showing ABBV-0805’s ability to selectively target soluble toxic α-synuclein aggregates.
The article entitled ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson’s disease focuses on the preclinical findings that continue to support ABBV-0805 for development in Parkinson’s disease. The data shows that ABBV-0805 selectively targets soluble toxic α-synuclein aggregates such as oligomers and protofibrils. In addition, ABBV-0805 displays a dose-dependent reduction of both soluble and insoluble α-synuclein aggregates in mice brains, preventing α-synuclein to spread, delaying motor-symptoms and prolonging the lifespan. Furthermore, binding of ABBV-0805 to pathological α-synuclein in postmortem brains of Parkinson’s disease patients has also been observed.
“I’m pleased to see the very encouraging data on ABBV-0805 published in a peer reviewed journal and we look forward to the continued development of this antibody as a potential disease-modifying treatment for patients with Parkinson’s disease,” BioArctic’s Head of Research Johanna Fälting.
For further information, please contact:
Gunilla Osswald, CEO
Phone: +46 8 695 69 30
Oskar Bosson, VP Communications and Investor Relations
Phone: +46 70 410 71 80